Realta Life Sciences secured an additional $40 million in the final tranche of its Series A financing, lifting total funding to more than $150 million. The company is developing a treatment for hypoxic ischemic encephalopathy (HIE), a condition affecting newborns after reduced oxygen and blood flow. The funding underscores sustained investor support for neonatal neurocritical care, where late-stage success depends on both clinical endpoints and practical implementation in the acute-care window. Realta’s series follows a mission-driven, family-office investment approach, according to the company. For the biotech ecosystem, the raise adds another example of capital funneling into specialized pediatric indications with high unmet need. The next step for Realta will be how this cash enables further development milestones and trial progression for its HIE candidate.